GoodRx vs Hims & Hers

Side-by-side comparison of AI visibility scores, market position, and capabilities

Hims & Hers leads in AI visibility (86 vs 39)
GoodRx logo

GoodRx

EmergingHealthcare

Prescription Savings

NASDAQ-listed (GDRX) prescription savings platform comparing prices across 70K+ pharmacies; $750M revenue with stock under pressure from Amazon Pharmacy and Cost Plus Drugs competition.

AI VisibilityBeta
Overall Score
D39
Category Rank
#396 of 596
AI Consensus
90%
Trend
stable
Per Platform
ChatGPT
37
Perplexity
35
Gemini
39

About

GoodRx is a Santa Monica-based prescription savings and healthcare price comparison platform that enables consumers to compare prices, access discount coupons, and find the lowest-cost pharmacy for their prescriptions — providing free price comparison tools across 70,000+ US pharmacies and a GoodRx Gold subscription ($9.99/month) with even lower prices on 1,000+ common medications. Listed on NASDAQ (NASDAQ: GDRX), GoodRx went public in September 2020 and generates approximately $750 million in annual revenue primarily from pharmaceutical industry fees and consumer subscription revenue.

Full profile
Hims & Hers logo

Hims & Hers

EmergingHealthcare

Telehealth Pharmacy

Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.

AI VisibilityBeta
Overall Score
A86
Category Rank
#8 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
88
Perplexity
92
Gemini
83

About

Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.

Full profile

AI Visibility Head-to-Head

39
Overall Score
86
#396
Category Rank
#8
90
AI Consensus
79
stable
Trend
stable
37
ChatGPT
88
35
Perplexity
92
39
Gemini
83
38
Claude
90
39
Grok
89

Key Details

Category
Prescription Savings
Telehealth Pharmacy
Tier
Emerging
Emerging
Entity Type
company
brand

Capabilities & Ecosystem

Capabilities

Only GoodRx
Prescription Savings
Only Hims & Hers
Telehealth Pharmacy
GoodRx is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.